Prosecution Insights
Last updated: October 25, 2026
Application No. 17/921,543

TREATMENT OF HER2 NEGATIVE, MAMMAPRINT HIGH RISK 2 BREAST CANCER

Non-Final OA §112
Filed
Oct 26, 2022
Priority
Apr 27, 2020 — EU 20171467.2 +1 more
Examiner
AEDER, SEAN E
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Agendia N.V.
OA Round
3 (Non-Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
817 granted / 1435 resolved
-3.1% vs TC avg
Strong +20% interview lift
Without
With
+20.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
75 currently pending
Career history
1516
Total Applications
across all art units

Statute-Specific Performance

§101
14.7%
-25.3% vs TC avg
§103
26.3%
-13.7% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1435 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/22/26 has been entered. Claim 30 has been added by Applicant. Claims 16-18, 20-23, and 30 are pending. Claims 16 and 20 have been amended by Applicant. Claims 16-18, 20-23, and 30 are currently under consideration. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. This Office Action contains New Rejections Necessitated by Amendments. Rejections Withdrawn All previous rejections are withdrawn. New Rejections Necessitated by Amendments Claim Rejections - 35 USC § 112 Claims 16-18, 20-23, and 30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 16-18, 20-23, and 30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, because 35 U.S.C. 112(b) and 35 U.S.C. 112 (pre-AIA ), second paragraph, require claims to particularly point-out and distinctly claim subject matter. The instant claims attempt to incorporate by reference to a specific table or figure; however, such incorporation is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. In the instant case, there is a practical way to define the invention in words. Incorporation by reference is a necessity doctrine, not for applicant’s convenience. See MPEP 2173.05(s). Response to Arguments In the Reply of 9/22/26, Applicant argues claim 16 is not improper because claim 16 refers to Table 2 to concisely identify genes of Table 2 used in the invention and does not incorporate Table 2 by reference in a manner contemplated by MPEP 2173.05(s). The amendments to the claims and the arguments found in the Reply of 9/22/26 have been carefully considered, but are not deemed persuasive. In regards to the argument that claim 16 is not improper because claim 16 refers to Table 2 to concisely identify genes of Table 2 used in the invention and does not incorporate Table 2 by reference in a manner contemplated by MPEP 2173.05(s), the examiner maintains the instant claims attempt to incorporate by reference to a specific table or figure; however, such incorporation is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. In the instant case, even though it would be more concise to recite “at least 70 genes listed in Table 2” than actually listing the 70 genes of Table 2, there is a practical way to define the invention in words – by listing the 70 genes. Incorporation by reference is a necessity doctrine, not for applicant’s convenience. See MPEP 2173.05(s). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN E AEDER whose telephone number is (571)272-8787. The examiner can normally be reached M-F 9am-6pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SEAN E AEDER/Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Show 1 earlier event
Jul 15, 2025
Non-Final Rejection mailed — §112
Jan 15, 2026
Response Filed
Jan 22, 2026
Final Rejection mailed — §112
Jul 27, 2026
Response after Non-Final Action
Jul 27, 2026
Notice of Allowance
Sep 22, 2026
Request for Continued Examination
Sep 23, 2026
Response after Non-Final Action
Oct 06, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758582
ANTI-CD33 ANTIBODIES AND USES THEREOF
4y 0m to grant Granted Oct 13, 2026
Patent 12760124
TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS
2y 8m to grant Granted Oct 13, 2026
Patent 12746272
METHOD OF TREATMENT OF CANCER OR TUMOUR
3y 8m to grant Granted Sep 29, 2026
Patent 12742780
METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER
3y 5m to grant Granted Sep 22, 2026
Patent 12735485
BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP
3y 0m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
77%
With Interview (+20.0%)
3y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1435 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month